Noninvasive Ventilatory Support
Non-invasive ventilation (NIV) is the delivery of oxygen (ventilation support) via a face mask and therefore eradicating the need of an endotracheal airway. NIV achieves comparative physiological benefits to conventional mechanical ventilation by decreasing the work of breathing and improving gas exchange. Research suggests that non-invasive ventilation after early extubation looks helpful in reducing the total days spent on invasive mechanical ventilation. The intervention is recognised as an adequate treatment for respiratory failure in chronic obstructive pulmonary disease, cardiogenic pulmonary oedema and other respiratory conditions without complications such as respiratory muscle weakness, upper airway trauma, ventilator-associated pneumonia, and sinusitis.
Related Conference of Noninvasive Ventilatory Support
15th International Conference on Pulmonary & Respiratory Medicine
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Noninvasive Ventilatory Support Conference Speakers
Recommended Sessions
- Asthma
- Bronchoscopy
- COPD
- COPD and Air Pollution
- COPD and Alpha-1 antitrypsin
- Cystic Fibrosis
- Diagnosis and Treatment of COPD
- Digital health for COPD Care
- Effect of COVID – 19 on Lungs
- Imaging in Pulmonary Hypertension
- Interstitial Lung Disease
- Interventional Pulmonology
- Lung Cancer Diagnosis & Treatment
- Lung Transplantation
- Noninvasive Ventilatory Support
- Pediatric Pulmonology & Critical care
- Pneumonia
- Pulmonary Rehabilitation
- Respiratory Diseases
- Self-Management and Prevention of COPD
- Sleep Apnea
- Tuberculosis
Related Journals
Are you interested in
- Advancements in Pulmonary Diagnostics - Respiratory 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - Respiratory 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic Obstructive Pulmonary Disease - Respiratory 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and Asthma - Respiratory 2024 (France)
- COVID-19 and Respiratory System - Respiratory 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Idiopathic Pulmonary Fibrosis - Respiratory 2024 (France)
- Interstitial Lung Disease - Respiratory 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung Cancer - Respiratory 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - Respiratory 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Obstructive Sleep Apnea - Respiratory 2024 (France)
- Occupational Lung Diseases - Respiratory 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pneumonia - Respiratory 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - Respiratory 2024 (France)
- Pulmonary Rehabilitation - Respiratory 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tuberculosis - Respiratory 2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)